Welcome to the international HTA database

Showing [23368 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Shear-wave elastography for liver fibrosis]
2019	Agency for Healthcare Research and Quality (AHRQ)	Comparative effectiveness of analgesics to reduce acute pain in the prehospital setting
2019	National Institute for Health and Care Excellence (NICE)	UrgoStart for treating diabetic foot ulcers and leg ulcers. NICE medical technologies guidance 42
2019	NIHR Health Services and Delivery Research programme	The changing general practitioner workforce: the development of policies and strategies aimed at retaining experienced GPs and those taking a career break in direct patient care (ReGROUP)
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Robot-assisted surgery in thoracic and visceral indications
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: Alphanate - von Willebrand disease]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Bendamustine as first line therapy for indolent non-Hodgkin’s lymphoma]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC)
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Erenumab in migraine prevention]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Annulus Fibrosus Repair after lumbar discectomy
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[4CMenB vaccine for primary vaccination]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Single/two-step scaffold-based cartilage repair in the knee and ankle joint
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Teriparatide in biphosphonate-resistant osteoporosis and high fracture risk]
2019	Agency for Care Effectiveness (ACE)	Video capsule endoscopy for diagnosing obscure gastrointestinal bleeding
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Radiofrequency denervation for lumbar and cervical facet joint pain – a systematic review
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Immunocyanin in urothelial bladder cancer
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Upper Airway Stimulation for Moderate-to-Severe Sleep Apnea. 1st Update 2019
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Central auditory processing disorder diagnosis]
2019	Agency for Care Effectiveness (ACE)	Ambulatory sleep study for diagnosing obstructive sleep apnoea
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Osteochondral allograft transplantation for the knee (or other joints)
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Selexipag in pulmonary hypertension]
2019	NIHR Health Technology Assessment programme	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Allograft for anterior and posterior cruciate ligament reconstruction
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Holmium laser enucleation in benign prostatic hyperplasia]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Human dermal allograft for massive rotator cuff tears
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[No-scalpel versus conventional vasectomy]
2019	NIHR Health Services and Delivery Research programme	PRESENT: Patient Reported Experience Survey Engineering of Natural Text: developing practical automated analysis and dashboard representations of cancer survey freetext answers
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate
2019	National Committee for Technology Incorporation (CONITEC)	[Diagnostic tests for thrombophilia in pregnancy]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Quantitative electroencephalography]
2019	Haute Autorite de sante (HAS)	[Lymphoseek (tilmanocept), radiopharmaceutical for diagnostic use]
2019	NIHR Health Technology Assessment programme	Stepped approach to improving sexual function after gynaecological cancer: the SAFFRON feasibility RCT
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Custom-made or customisable 3D printed implants and cutting guides versus non- 3D printed standard implants and cutting guides for improving outcome in patients undergoing knee, maxillofacial, or cranial surgery
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Reiki therapy in anxiety, depression and pain]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision)]
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Hip arthroscopy for painful hip treatment]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Durvalumab (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Regorafenib for previously treated advanced hepatocellular carcinoma. NICE technology appraisal guidance 555
2019	NIHR Health Technology Assessment programme	Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Irreversible electroporation for the treatment of liver and pancreatic cancer
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Prostate rectum spacing in prostate radiation therapy]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (head and neck squamous cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Darvadstrocel for treating complex perianal fistulas in Crohn's disease. NICE technology appraisal guidance 556
2019	NIHR Health Technology Assessment programme	Anaesthetic analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening and prevention programmes for children and adolescents from 6 to 14 years. Results from selected countries and recommendations from evidence-based guidelines
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Endovascular thrombectomy in acute ischemic stroke]
2019	National Institute for Health and Care Excellence (NICE)	Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal). NICE technology appraisal guidance 560
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening for Diabetes mellitus: guideline recommendations
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Deep anterior lamellar keratoplasty in keratoconus]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Negative pressure wound therapy for wounds healing by secondary intention]
2019	National Institute for Health and Care Excellence (NICE)	Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Shoulder prosthesis in complex proximal humeral fractures]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Ingenol mebutate (actinic keratosis) - Addendum to Commission A18-55]
2019	National Institute for Health and Care Excellence (NICE)	Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 562
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	FoundationOne®CDx: genetic profiling of solid tumours
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Implantable cardiac monitors in syncope of unknown etiology]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer. NICE technology appraisal guidance 563
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Rapid on-site evaluations of cytological punctures]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Benralizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 565
2019	NIHR Health Technology Assessment programme	Manualised cognitive behavioural therapy in treating depression in advanced cancer: the CanTalk RCT
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Per-oral endoscopic myotomy (POEM) in achalasia]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2019	National Institute for Health and Care Excellence (NICE)	Cochlear implants for children and adults with severe to profound deafness. NICE technology appraisal guidance 566
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pharma: Disclosure of transfers of value in Austria 2018. Update of the systematic analysis 2015
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Optical coherence tomography: usefulness in glaucoma, diabetic retinopathy and age-related macular degeneration]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of strategies to prevent urinary tract infections related to urethral catheters in critically ill patients in intensive care units]
2019	National Institute for Health and Care Excellence (NICE)	Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies. NICE technology appraisal guidance 567
2019	NIHR Health Technology Assessment programme	Cabozantinib and vandatinib for treating advanced or metastatic medullary thyroid cancer (ID56)
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Video head impulse test in vertigo]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evidence on the personalization of population-based breast cancer screening]
2019	National Institute for Health and Care Excellence (NICE)	Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal). NICE technology appraisal guidance 568
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Screening programs for children and adolescents from 6 to 18 years. Results on selected countries, Austrian screening programmes and recommendations from evidence-based guidelines
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Palivizumab for the prevention of respiratory syncytial virus lower respiratory tract infections]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Cerenkov lluminescence imaging system for intraoperative assessment of surgical margins in breast, prostate, and gastrointestinal cancer]
2019	National Institute for Health and Care Excellence (NICE)	Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer. NICE technology appraisal guidance 569
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Sacral nerve stimulation/neuromodulation in bladder and/or bowel incontinence]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Semaglutide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2019	Agency for Healthcare Research and Quality (AHRQ)	Long-term drug therapy and drug holidays for osteoporosis fracture prevention: a systematic review
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[MALDI-TOF mass spectrometry technology in the diagnosis of antibiotic resistance]
2019	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 570
2019	NIHR Health Technology Assessment programme	An evaluation of the feasibility of conducting a randomised clinical trial to evaluate the clinical and cost-effectiveness of a more permissive temperature threshold for antipyretic intervention in critically ill children with fever due to infection: the FEVER feasibility study
2019	Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)	Cervical Carcinoma Prevention - Implementation of an HPV screening test for early detection of cervical cancer in Austria
2019	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge, state of practice: Use of direct oral anticoagulants and warfarin in the context of atrial fibrillation and venous thromboembolism]
2019	Institute for Clinical Effectiveness and Health Policy (IECS)	[Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2019	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tofacitinib (psoriatic arthritis) - Addendum to Commission A18-51]
2019	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Economic, organization and safety impact of drug robotic dispensing in Spanish hospitals]
2019	National Institute for Health and Care Excellence (NICE)	Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib. NICE technology appraisal guidance 571
2019	NIHR Health Technology Assessment programme	Interferon gamma release assays for Diagnostic Evaluation of Active tuberculosis (IDEA): test accuracy study and economic evaluation